BPC Podcast Weekly Watchlist May 29, 2026

Hinzugefügt: 2026-06-03

[00:00:10]Biotech investors, the end of quarter catalyst window is heating up and three names stand out because the next update could materially reshape how the market values each company. First is Novocure, ticker NVCR. The key catalyst is final data from the EF-32 trial and phase three study of Optune. Optune uses tumor treating fields or TT Fields delivered at 200 kHz to the brain. These electric fields apply physical forces that can disrupt cancer cells because those cells contain electrically charged components.

[00:00:38]The pivotal metric is overall survival measured over a 5-year time frame. The big question is whether starting Optune earlier during radiation therapy and temozolomide improves outcomes versus this current standard of care where Optune is added later during maintenance temozolomide.

[00:00:53]>> [snorts] >> With approved Optune products and final data anticipated in the second quarter of 2026, this is a major validation moment for the broader TT Fields platform.

[00:01:03]Next is Ionis Pharmaceuticals, ticker IONS. The catalyst is a June 30th, 2026 PDUFA priority review date for olezarsen in severe hypertriglyceridemia.

[00:01:14]Olezarsen, also known as ISIS 678354, comes from Ionis's RNA targeted therapy platform. The phase three core study enrolled 617 patients and measured percent change from baseline in fasting triglycerides versus placebo. That triglyceride reduction is the number investors need to watch. Prior phase three data showed statistically significant reductions at both the 80 mg and 50 mg doses, including a 72% placebo-adjusted mean reduction in fasting triglycerides at 6 months, sustained through 12 months. The asymmetry is commercial. Olezarsen is positioned against a US severe hypertriglyceridemia population of more than 3 million people. Third is Viridian Therapeutics, ticker VRDN. The catalyst is the June 30th, 2026 PDUFA priority review date for VRDN-001 in thyroid eye disease.

[00:02:04]The BLA is supported by THRIVE and THRIVE 2, two of the largest phase 3 TED trials conducted to date across active and chronic disease.

[00:02:13]The key clinical metrics are proptosis and diplopia, where VRDN-001 showed clinically meaningful improvements after five infusions along with rapid onset, durable responses, and general tolerability.

[00:02:25]The context is commercial execution.

[00:02:27]Viridian is preparing for a potential mid-2026 US launch in an annualizing $2 billion US TED market.

[00:02:34]That's all for today. For more biotech catalysts, trial readouts, and PDUFA dates, check out www.biopharmcatalyst.com.